AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

PrecisionMed Launches Traumatic Brain Injury Cerebral Spinal Fluid Registry

February 10, 2020 GMT

SAN DIEGO--(BUSINESS WIRE)--Feb 10, 2020--

PrecisionMed Inc., the world’s leading supplier of human cerebral spinal fluid (CSF), today announced enrollment of the first donor into the PrecisionMed Traumatic Brain Injury Registry (TBI). The PrecisionMed TBI Registry is a biological sample bank of DNA, longitudinal CSF, RNA, serum and plasma linked to clinical data utilizing PrecisionMed’s clinical data procurement and clinical sample management capabilities. The PrecisionMed TBI Registry is expected to be of value for the discovery and/or validation of biomarkers for neurological disease.

The PrecisionMed TBI Registry will enroll up to 2000 well-characterized participant donors who will be recruited, evaluated, clinically studied, and sampled from up to 10 experienced investigative sites in the US. Key aspects of donors’ clinical status will be evaluated every four months with simultaneous biological sampling. These longitudinally collected, data-accompanied biospecimens will be available upon request through PrecisionMed. Custom requests for additional sample types, as well as more complex clinical, laboratory and/or radiographic evaluations within selected subpopulations will be entertained as the registry matures.

“This project may yield important information for drug discovery, disease diagnosis, prediction of response to treatments and disease prognosis. The track record of PrecisionMed in this kind of collection is excellent and bodes well that the data and samples will be of the highest quality,” said John Flax, M.D., President and CEO of PrecisionMed. “Accurate phenotyping in TBI is critical for relating clinical changes to alterations in biomarkers and the development of disease-modifying treatments.”

The PrecisionMed TBI Registry, uses serial clinical evaluations and biological sampling for correlation of clinical change with biomarkers. PrecisionMed has extensive experience with longitudinal and single visit CSF banking projects in ALS, Alzheimer’s disease, mild cognitive impairment, schizophrenia, Parkinson’s disease, multiple sclerosis, MSA and “True Normal” populations. These ongoing sample collections are an acknowledged, valuable source of highly annotated neuroscience samples, including CSF, to the research community worldwide.

About PrecisionMed Inc.

PrecisionMed Inc., founded in 1994, is a privately held human biobank in the San Diego, California, area. PrecisionMed’s sample bank is a repository of human blood, DNA, RNA, PBMC, serum, plasma, urine, CSF as well as tumor samples linked to detailed de-identified audited clinical data. Samples are available to the pharmaceutical industry to enhance drug discovery and development, therapeutic target validation and molecular diagnostic product development. PrecisionMed provides customers access to samples with associated clinical information from a population of disease-specific donors and healthy matched controls. PrecisionMed is the world’s only supplier of CSF from “True Normal” donors. PrecisionMed is expanding its collections to include additional neuropsychiatric, neurodegenerative, oncology and other diseases. PrecisionMed offers custom sample collections in any disease area as well as custom CSF collections.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200210005157/en/

CONTACT: PrecisionMed Inc.

John Flax, MD

858-847-0117 X 215

johnflax@precisionmed.com

www.precisionmed.com PrecisionMed Inc.

Cassandra Maxwell, MPH

858-847-0117 X 209

cassandramaxwell@precisionmed.com

www.precisionmed.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH GENETICS OTHER HEALTH OTHER SCIENCE RESEARCH SCIENCE BIOTECHNOLOGY

SOURCE: PrecisionMed Inc.

Copyright Business Wire 2020.

PUB: 02/10/2020 09:00 AM/DISC: 02/10/2020 09:01 AM

http://www.businesswire.com/news/home/20200210005157/en